至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

PB1-F2 protein of highly pathogenic influenza A (H7N9) virus selectively suppresses RNA-induced NLRP3 inflammasome activation through inhibition of MAVS-NLRP3 interaction

J Leukoc Biol. 2020; 
Pak-Hin Hinson Cheung, Zi-Wei Ye, Tak-Wang Terence Lee, Honglin Chen, Chi-Ping Chan, Dong-Yan Jin
Products/Services Used Details Operation
Bacterial Expression … Finally, monoclonal mouse anti‐H7N9 PB1‐F2 antibody was raised by Genscript (Piscataway, NJ, USA) using full‐length recombinant PB1‐F2 protein of A/Zhejiang/DTID‐ZJU01/2013 (H7N9) expressed from E. coli as immunogen … Get A Quote

摘要

Infection with seasonal as well as highly pathogenic avian influenza A virus (IAV) causes significant morbidity and mortality worldwide. As a major virulence factor, PB1-F2 protein of IAV affects the severity of disease through multiple mechanisms including perturbation of host innate immune response. Macrophages are known to phagocytose extracellular PB1-F2 protein aggregate, leading to hyperactivation of NLRP3 inflammasome and excessive production of IL-1β and IL-18. On the other hand, when expressed intracellularly PB1-F2 suppresses NLRP3 inflammasome maturation. How extracellular and intracellular PB1-F2 orchestrates to drive viral pathogenesis remains unclear. In this study, we demonstrated the suppressio... More

关键词

H7N9 virus, MAVS, NLRP3, PB1-F2 virulence factor, avian influenza A virus, inflammasome activation